Evidence map›Paper›PMID 35513874›Full record

ArticleJournal of ovarian research2022

A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer.

Min Zhou, Tao Wu, Yuan Yuan, Shu-Juan Dong, Zhi-Ming Zhang, Yan Wang, Jing Wang

Abstract read
In one paragraph

Article in Journal of ovarian research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Min Zhou *Department of Gynecologic Cancer, Shaanxi Provincial Cancer Hospital, No. 309 Yanta West Road, Shaanxi, 710061, Xi'an, People's Republic of China.
Tao Wu *Department of Gynecologic Cancer, Shaanxi Provincial Cancer Hospital, No. 309 Yanta West Road, Shaanxi, 710061, Xi'an, People's Republic of China.
Yuan YuanDepartment of Gynecologic Cancer, Shaanxi Provincial Cancer Hospital, No. 309 Yanta West Road, Shaanxi, 710061, Xi'an, People's Republic of China.
Shu-Juan DongDepartment of Obstetrics and Gynecology, Shaanxi Provincial Rehabilitation Hospital, Xi'an, Shaanxi, People's Republic of China.
Zhi-Ming ZhangDepartment of Clinical Laboratory, Xi'an Central Hospital, Xi'an, Shaanxi, People's Republic of China.
Yan WangDepartment of Gynecology, Xi'an Central Hospital, No.161 five West Road, Xi'an, Shaanxi, People's Republic of China. wy34003@163.com.
Jing WangDepartment of Gynecologic Cancer, Shaanxi Provincial Cancer Hospital, No. 309 Yanta West Road, Shaanxi, 710061, Xi'an, People's Republic of China. jingwang_sxpth@126.com.ORCID http://orcid.org/0000-0001-5845-2753

Funding

Basic Research Plan of Shaanxi Provincial Cancer Hospital SC211002Natural Science Foundation of Shaanxi Province 2018JM7138Natural Science Foundation of Shaanxi Province 2020JM-679Science and Technology Project of Xi'an 201805098YX6SF32(3)The Cancer Research Youth Science Foundation of Chinese Anti-Cancer Association CAYC18A27
6 · The paper itself

Abstract

backgroundOvarian cancer (OVC) is a devastating disease worldwide; therefore the identification of prognostic biomarkers is urgently needed. We aimed to determine a robust microRNA signature-based risk score system that could predict the overall survival (OS) of patients with OVC.

methodsWe extracted the microRNA expression profiles and corresponding clinical data of 467 OVC patients from The Cancer Genome Atlas (TCGA) database and further divided this data into training, validation and complete cohorts. The key prognostic microRNAs for OVC were identified and evaluated by robust likelihood-based survival analysis (RLSA) and multivariable Cox regression. Time-dependent receiver operating characteristic (ROC) curves were then constructed to evaluate the prognostic performance of these microRNAs. A total of 172 ovarian cancer samples and 162 normal ovarian tissues were used to verify the credibility and accuracy of the selected markers of the TCGA cohort by quantitative real-time polymerase chain reaction (PCR).

resultsWe successfully established a risk score system based on a six-microRNA signature (hsa-miR-3074-5p, hsa-miR-758-3p, hsa-miR-877-5p, hsa-miR-760, hsa-miR-342-5p, and hsa-miR-6509-5p). This microRNA based system is able to characterize patients as either high or low risk. The OS of OVC patients, with either high or low risk, was significantly different when compared in the training cohort (p < 0.001), the validation cohort (p < 0.001) and the complete cohort (p < 0.001). Analysis of clinical samples further demonstrated that these microRNAs were aberrantly expressed in OVC tissues. The six-miRNA-based signature was correlated with the prognosis of OVC patients (p < 0.001).

conclusionsThe study established a novel risk score system that is predictive of patient prognosis and is a potentially useful guide for the personalized treatment of OVC patients.

Indexed as

MicroRNAsOvarian NeoplasmsBiomarkers, TumorCarcinoma, Ovarian EpithelialFemaleGene Expression ProfilingHumansLikelihood FunctionsPrognosisRisk FactorsBiomarkers, TumorMicroRNAsMIRN3074 microRNA, humanMIRN758 microRNA, humanMIRN760 microRNA, humanMIRN877 microRNA, humanBioinformatics analysismicroRNA signatureOvarian cancerPrognosisTCGA

Identifiers

PMID35513874
PMCPMC9074233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.